Skip to content
General-news — Technology — Headquarters — Geneticist — Fitness-and-exercise — Nature — Dismissal — Probably — Science — News — Decode — Health-and-wellness — Workplace-wellness

Sudden Firing Leads to Stefansson's Unanticipated Contentment: "I find myself a Merry Old Gentleman now"

Geneticist Kári Stefánsson, founder of deCode Genetics, expressed no shock over his unexpected resignation from the firm he helmed for almost three decades. In an interview with mbl.is, Stefánsson characterized his departure as a predictable outcome due to contrasting scientific focus between...

,   and  Administrator
3 min read
Geneticist Kári Stefánsson, founder of deCode Genetics, expresses no shock over his sudden...
Geneticist Kári Stefánsson, founder of deCode Genetics, expresses no shock over his sudden termination from the company he headed for close to three decades. In an interview with mbl.is, Stefánsson attributes his departure to opposing scientific objectives between himself and Amgen, deCode's parent company.

Sudden Firing Leads to Stefansson's Unanticipated Contentment: "I find myself a Merry Old Gentleman now"

Fired Geneticist Kári Stefánsson Speaks Out

In an exclusive interview with mbl.is, Kári Stefánsson, the celebrated geneticist and founder of deCode Genetics, discussed his sudden dismissal from the company he led for nearly three decades. The parting of ways, Stefánsson explains, was a result of differing scientific priorities between him and Amgen, deCode's parent company.

A Contentious Meeting in California

The termination of Stefánsson's tenure occurred during a meeting at Amgen headquarters in Thousand Oaks, California. Initial indications suggested the gathering would center on a potential collaboration with Abu Dhabi. However, the unexpected outcome was Stefánsson being informed that his association with deCode was at an end. Simultaneously, longtime colleagues Patrick Sulem and Daníel Guðbjartsson were surreptitiously excused from the gathering and whisked back to Iceland aboard a private jet.

Incompatible Styles

Stefánsson believes the decision was rooted in a fundamental disagreement on methodologies: Amgen gravitates towards targeted drug development, while Stefánsson's passions lie in expansive, investigative research. "When it boils down to scientific enthusiasm, I'm a bit of a minstrel, chasing everything from the stars to the ground," he remarks.

Despite the unceremonious nature of his departure, Stefánsson displays no ill-will. "I've become a jolly old soul now," he says. He intends to finish two books he's been working on and is open to continuing his research in genetics elsewhere.

His accomplishments have positioned Iceland at the cutting edge of global genetic research, and despite parting ways, his thirst for knowledge remains insatiable.

Amgen vs. Kári Stefánsson: A Clash of Scientific Ideologies

Amgen, a leading biotechnology company, focuses on precision medicine and drug development by integrating omics technologies like genomics, transcriptomics, and proteomics. In contrast, Kári Stefánsson's work at deCODE genetics revolves around large-scale genetic studies in populations to identify genetic risk factors for various diseases. Both share a commitment to genetic research, but their approaches differ.

Amgen delves into understanding disease mechanisms using multiple omics layers, while incorporating advanced technologies like AI to enhance drug discovery. Stefánsson's focus, meanwhile, has been population genetics and applying this understanding to predict disease risks and develop preventive measures.

The clash of philosophies underpins the sudden end to Stefánsson's tenure at deCode Genetics, with Amgen favoring targeted drug development and Stefánsson yearning for exploratory research.

  1. Kári Stefánsson, now a free-agent geneticist, intends to complete two books and explore new opportunities in the field of genetics, reflecting his unquenchable thirst for knowledge.
  2. The dismissal of Kári Stefánsson was not without controversy, as it was rooted in a fundamental disagreement on methodologies between him and Amgen, his former employer.
  3. In an interview, Stefánsson elaborated on the disparity in their scientific priorities, stating that while Amgen focuses on targeted drug development, his passion lies in expansive, investigative research.
  4. The news of Stefánsson's departure was accompanied by the secret recall of his longtime colleagues from a meeting at Amgen headquarters in Thousand Oaks, California.
  5. The onset of the science-driven wellness movement has seen a convergence of technology and genetics, with companies like Amgen leading the charge in precision medicine and drug development.
  6. Despite the clash in ideologies, Stefánsson's contributions have served to enhance Iceland's standing as a global leader in genetic research, reflecting the vital role education and self-development play in fostering innovation.
  7. As the landscape of general news evolves to incorporate more stories from the exciting world of science and technology, the dismissal of Stefánsson from deCode Genetics has emerged as a notable event in the realm of health and wellness, fitness and exercise, and education and self-development.

Read also:

    Related

    Latest